HAVCR1 in cancer: A systematic review of its dual-faceted role as a biomarker and therapeutic target

IF 1 Q4 GENETICS & HEREDITY Gene Reports Pub Date : 2025-02-25 DOI:10.1016/j.genrep.2025.102178

Amirali Soltaninegar , Fatemeh Sadat Jalilzadeh Ghahi , Sepideh Hosseini , Najaf Allahyari Fard

{"title":"HAVCR1 in cancer: A systematic review of its dual-faceted role as a biomarker and therapeutic target","authors":"Amirali Soltaninegar , Fatemeh Sadat Jalilzadeh Ghahi , Sepideh Hosseini , Najaf Allahyari Fard","doi":"10.1016/j.genrep.2025.102178","DOIUrl":null,"url":null,"abstract":"<div><div>Hepatitis A virus cellular receptor 1 (HAVCR1), also known as KIM-1 in kidney diseases and TIM-1 or CD365 in immunology, is a class 1 integral membrane glycoprotein member that plays a pivotal role in cancer progression, diagnosis, and potential treatment. This review study aims to explore the various aspects of the HAVCR1 protein, focusing on its role as a potential biomarker and therapeutic target in different types of cancers and analyze the correlation of HAVCR1 with prognosis, underlying molecular mechanisms, and its clinical potential in cancer diagnosis and treatment. In cancers such as RCC, ESCA, LIHC, PAAD, LUAD, and OV, HAVCR1 is associated with poor prognosis, whereas in others like COAD, RB, SKCM, and BLCA, it correlates with improved outcomes. HAVCR1 contributes to cancer progression through the MAPK/ERK and PI3K/AKT pathways, which regulate immune suppression, cell growth, survival, migration, and angiogenesis. Its expression level, shedding, and localization significantly influence its role in cancer in the plasma or internal membranes. The release of the HAVCR1 ectodomain during shedding and its detectability in urine, blood, and cerebrospinal fluid highlight its potential as a biomarker for diagnosing specific cancers. Furthermore, HAVCR1 represents a promising target for therapeutic interventions in oncology.</div></div>","PeriodicalId":12673,"journal":{"name":"Gene Reports","volume":"39 ","pages":"Article 102178"},"PeriodicalIF":1.0000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gene Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452014425000512","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Hepatitis A virus cellular receptor 1 (HAVCR1), also known as KIM-1 in kidney diseases and TIM-1 or CD365 in immunology, is a class 1 integral membrane glycoprotein member that plays a pivotal role in cancer progression, diagnosis, and potential treatment. This review study aims to explore the various aspects of the HAVCR1 protein, focusing on its role as a potential biomarker and therapeutic target in different types of cancers and analyze the correlation of HAVCR1 with prognosis, underlying molecular mechanisms, and its clinical potential in cancer diagnosis and treatment. In cancers such as RCC, ESCA, LIHC, PAAD, LUAD, and OV, HAVCR1 is associated with poor prognosis, whereas in others like COAD, RB, SKCM, and BLCA, it correlates with improved outcomes. HAVCR1 contributes to cancer progression through the MAPK/ERK and PI3K/AKT pathways, which regulate immune suppression, cell growth, survival, migration, and angiogenesis. Its expression level, shedding, and localization significantly influence its role in cancer in the plasma or internal membranes. The release of the HAVCR1 ectodomain during shedding and its detectability in urine, blood, and cerebrospinal fluid highlight its potential as a biomarker for diagnosing specific cancers. Furthermore, HAVCR1 represents a promising target for therapeutic interventions in oncology.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Gene Reports Biochemistry, Genetics and Molecular Biology-Genetics

CiteScore

3.30

自引率

7.70%

发文量

246

审稿时长

49 days

期刊介绍： Gene Reports publishes papers that focus on the regulation, expression, function and evolution of genes in all biological contexts, including all prokaryotic and eukaryotic organisms, as well as viruses. Gene Reports strives to be a very diverse journal and topics in all fields will be considered for publication. Although not limited to the following, some general topics include: DNA Organization, Replication & Evolution -Focus on genomic DNA (chromosomal organization, comparative genomics, DNA replication, DNA repair, mobile DNA, mitochondrial DNA, chloroplast DNA). Expression & Function - Focus on functional RNAs (microRNAs, tRNAs, rRNAs, mRNA splicing, alternative polyadenylation) Regulation - Focus on processes that mediate gene-read out (epigenetics, chromatin, histone code, transcription, translation, protein degradation). Cell Signaling - Focus on mechanisms that control information flow into the nucleus to control gene expression (kinase and phosphatase pathways controlled by extra-cellular ligands, Wnt, Notch, TGFbeta/BMPs, FGFs, IGFs etc.) Profiling of gene expression and genetic variation - Focus on high throughput approaches (e.g., DeepSeq, ChIP-Seq, Affymetrix microarrays, proteomics) that define gene regulatory circuitry, molecular pathways and protein/protein networks. Genetics - Focus on development in model organisms (e.g., mouse, frog, fruit fly, worm), human genetic variation, population genetics, as well as agricultural and veterinary genetics. Molecular Pathology & Regenerative Medicine - Focus on the deregulation of molecular processes in human diseases and mechanisms supporting regeneration of tissues through pluripotent or multipotent stem cells.